Received: 10.02.2020 Accepted: 12.08.2020 Published: 22.01.2021

Original paper

POLISH J<u>ournal *o*f Radiology</u>

Advanced intra-tumoural structural characterisation of hepatocellular carcinoma utilising FDG-PET/CT: a comparative study of radiomics and metabolic features in 3D and 2D

Mohamed Houseni^{1A,D,E}, Menna Allah Mahmoud^{1A,B,C,D,E,F}, Salwa Saad^{2E}, Fathi ElHussiny^{2A}, Mohammed Shihab^{2D,E}

¹Department of Medical Imaging, National Liver Institute, Menoufia University, Egypt ²Department of Physics, Faculty of Science, Tanta University, Tanta, Egypt

Abstract

Purpose: The aim of our work is to evaluate the correlation of two-dimensional (2D) and three-dimensional (3D) radiomics and metabolic features of hepatocellular carcinoma (HCC) with tumour diameter, staging, and metabolic tumour volume (MTV).

Material and methods: Thirty-three patients with HCC were studied using ¹⁸F-fluorodeoxyglucose positron-emission tomography with computed tomography (¹⁸F [FDG] PET/CT). The tumours were segmented from the PET images after CT correction. Metabolic parameters and 35 radiomics features were compared using 2D and 3D modes. The metabolic parameters and tumour morphology were compared using 2 different types of software. Tumour heterogeneity was studied in both metabolic parameters and radiomics features. Finally, the correlation between the metabolic and radiomics features in 3D mode, as well as tumour morphology and staging according to the American Joint Committee on Cancer (AJCC) staging were studied.

Results: Most of the metabolic parameters and radiomics features are statically stable through the 2D and 3D modes. Most of the 3D mode features show a correlation with metabolic parameters; the total lesion glycolysis (TLG) shows the highest correlation, with a Spearman correlation coefficient (rs) of 0.9776. Also, the grey level run length matrix/ run length non-uniformity (GLRLM_RLNU) from radiomics features exhibits a correlation with a Spearman correlation coefficient of 0.9733. Maximum tumour diameter is correlated with TLG and GLRLM_RLNU, with rs equal to 0.7461 and 0.7143, respectively. Regarding AJCC staging, some features show a medium but prognostic correlation. In the case of 2D-mode features, all metabolic and radiomics features show no significant correlation with MTV, AJCC staging, and tumour maximum diameter.

Conclusions: Most of the normal metabolic parameters and radiomics features are statistically stable through the 3D and 2D modes. 3D radiomics features are significantly correlated with tumour volume, maximum diameter, and staging. Conversely, 2D features have negligible correlation with the same parameters. Therefore, 3D mode features are preferable and can accurately evaluate tumour heterogeneity.

Key words: hepatocellular carcinoma, FDG-PET-CT, heterogeneity, radiomics.

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancerrelated death [1]. HCC is an extremely heterogeneous disease, and intratumour heterogeneity is a recognised fact within each specific tumour. Heterogeneity could involve molecular, morphological, and immunohistochemical characteristics.

The pathologic classification of HCC is based on the degree of cellular difference. The cancer tissue of two different histological grades may be present in the same

Correspondence address:

Menna Allah Mahmoud, Department of Medical Imaging, National Liver Institute, Menoufia University, Gamal Abdelnasser street, Shebin ElKom, Egypt, e-mail: menna22a@yahoo.com

Authors' contribution:

A Study design · B Data collection · C Statistical analysis · D Data interpretation · E Manuscript preparation · F Literature search · G Funds collection

This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0). License (https://creativecommons.org/licenses/by-nc-nd/4.0/). tumour. Intratumor heterogeneity of HCC has a prognostic value [2].

It is hard to survey intra-tumoural heterogeneity with conventional testing or biopsy because it is difficult to cover the full degree of phenotypic or hereditary variety inside a tumour. Imaging modalities such as X-ray, ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) show a good and non-intrusive technique for evaluating the heterogeneity inside a tumour. A limitation that applies to all imaging modalities is that the image interpretation is based on a visual process. However, there are features within each image that may not be appreciated readily by the naked eye [3].

Recently, there has been extensive effort in the medical imaging community to obtain correlations between imaging features and tumour heterogeneity; an approximation for this concern is radiomics, which is a new technique that depends on the extraction of more data from biomedical images that cannot be investigated by the naked eye. This term was used for first time by Lambin *et al.*, who investigated quantitative image analysis such as texture analysis to assess tumour heterogeneity [4]. Several studies demonstrated a promising role for radiomics in cancer diagnosis, staging, and treatment assessment [5,6].

No standardisation has yet been developed for radiomics. Radiomics features are variable through many factors such as scanners, test-retest, observers, segmentation methods, and image reconstruction [7-9]. In addition, the mode of imaging may have an influence on radiomics. Texture analysis was performed in 2D mode. However, the advancements in 3D information acquisition and the high spatial resolution allow better capture of tissue properties [10]. Few studies have looked at the differences between radiomics or textural features in 3D and 2D modes utilising MRI or CT [11,12]. Ortiz-Ramón *et al.* introduced a radiomics approach on MRI of cancer lesions including lung cancer and melanoma [13].

The aim of our work was to evaluate the correlation of 2D and 3D radiomics and metabolic features of hepatocellular carcinoma with tumour diameter, staging, and metabolic tumour volume.

Material and methods

Patients

This retrospective study included 33 consecutive patients with HCC proven by histopathology (29 males and 4 females) between November 2016 and April 2018. Patients were referred to our department primarily to investigate the extra-hepatic disease before starting an appropriate management plan. The average age was 57.7 years (range 39-77). Disease stage was assigned by a tumour board committee and based on the American Joint Committee on Cancer (AJCC) cancer staging manual 2017 [14]. The primary HCC was diagnosed by histopathology, the nodal and metastatic disease was established with reference to dedicated imaging, histopathology/histocytology of suspicious lesions when indicated to change line of management as well as the clinical assessment and follow-up. After staging, patients were referred to a multidisciplinary HCC panel including an oncologist, surgeon, hepatologist, and interventional radiologist. The management plan was implemented based on the Barcelona Clinic Liver Cancer (BCLC) system and its updates, which incorporates tumour morphology, liver function, and health performance status along with treatmentdependent variables [15,16].

The study was approved by the institutional review board (IRB), and informed consent was waved.

Imaging techniques

The study was performed using a PET/CT scanner (Siemens Biograph 128-mCT). The patients were positioned in the PET/CT scanner approximately after injection of FDG intravenously the patients injected according to their weight by 0.1 mCi or 3.7 MBq for each kg. A non-contrast CT scan was acquired from the base of the skull to the upper high region and used for attenuation correction. Images size was 200×200 pixels; slice thickness = 1 mm.

Image processing and analysis

Imaging interpretation and analysis were performed and revised by a qualified radiologist with 15 years' experience in reading PET/CT. The tumours were segmented from the PET images after CT correction, using a semiautomatic method by ITK-snap software version 3.6.0 in 2D mode. In 3D mode the Pet scan segmented directly using a semiautomatic method in LIFEx package version 4.0.0 (https://www.lifexsoft.org/) [17]. The metabolic parameters and texture features were extracted using the LIFEx package. Figure 1 shows a diagram of the workflow of radiomics extraction, and Figure 2 shows a PET scan before and after delineation in the LIFEx package.

Metabolic parameters

The standardised uptake value (SUV) is defined as the tissue concentration of tracer, as measured by a PET scanner, divided by the activity injected divided by body weight [18]. There are many parameters related to SUV that can be useful for cancer diagnosis and staging.

 SUV_{max} : The maximum SUV value at the region of interest, which is the commonly used SUV clinically; however, some works show that another SUV factor can give a global view for tumours, such as metabolic tumour volume (MTV) and TLG.

 $\mathbf{SUV}_{\mathrm{mean}}$: The average SUV value at the region of interest.



Figure 1. The workflow of standardised uptake value (SUV) parameters and radiomics features extraction



Figure 2. Coronal positron-emission tomography (PET) images of a 59-year-old male with hepatocellular carcinoma before (A) and after (B) delineation of the liver lesion using LIFEx package

SUV_{min}: The minimum SUV value at the region of interest.

Metabolic tumour volume (MTV): Measures the active volume in ml.

Total lesion glycolysis (TLG): Is defined as the product of SUV_{mean} and MTV [19].

Intra-tumour heterogeneity

The ¹⁸F-FDG uptake heterogeneity was estimated using the coefficient of variation (COV), defined as the ratio between the standard deviation of SUV values and the mean SUV value within the delineated MTV [20].

SUV parameters are referred to as usual metabolic parameters; MTV and TLG are referred to as global metabolic parameters [21].

Texture features

Thirty-five radiomics features are studied. Histogram indices derived after determination of bin width; the grey level co-occurrence matrix (GLCM) takes into consideration the arrangements of pairs of voxels to calculate textural indices, and the neighbourhood grey-level different matrix (NGLDM) corresponds to the distinction of grey-level between one voxel and its 26 neighbours in 3 dimensions. The grey-level run length matrix (GLRLM) provides the scale of consistent runs for every grey-level. The grey-level zone length matrix (GLZLM) provides data on the scale of consistent zones for every grey-level in 3 dimensions.

Table 1 summarises all of the different features included in this study. More details about the radiomics features used

Table 1. Summary of the features included in this study

Feature name	Feature index	Feature type		
The minimum SUV	SUV _{min} (SUV)	SUV/normal metabolic parameters		
The average SUV	SUV _{mean} (SUV)	SUV/normal metabolic parameters		
The standard deviation of SUV	SUV _{std} (SUV)	SUV/normal metabolic parameters		
The maximum SUV	SUV _{max} (SUV)	SUV/normal metabolic parameters		
The coefficient of variation	SUV _(std/mean)	SUV/normal metabolic parameters		
Total lesion glycolysis	TLG (ml)	Global metabolic parameters		
Metabolic tumour volume	(MTV) Volume (ml)	Global metabolic parameters		
Skewness	HISTO_Skewness	Histogram indices		
Kurtosis	HISTO_Kurtosis	Histogram indices		
Entropy	HISTO_Entropy_log10	Histogram indices		
Entropy	HISTO_Entropy_log2	Histogram indices		
Energy	HISTO_Energy	Histogram indices		
Homogeneity	GLCM_Homogeneity	The grey level co-occurrence matrix (GLCM)		
Energy	GLCM_Energy	GLCM		
Contrast	GLCM_Contrast	GLCM		
Correlation	GLCM_Correlation	GLCM		
Entropy	GLCM_Entropy_log10	GLCM		
Entropy	GLCM_Entropy_log2	GLCM		
Dissimilarity	GLCM_Dissimilarity	GLCM		
Short-run emphasis	GLRLM_SRE	The grey-level run length matrix (GLRLM)		
Long-run emphasis	GLRLM_LRE	GLRLM		
Low grey-level run emphasis	GLRLM_LGRE	GLRLM		
High grey-level run emphasis	GLRLM_HGRE	GLRLM		
Short-run low grey-level emphasis	GLRLM_SRLGE	GLRLM		
Short-run high grey-level emphasis	GLRLM_SRHGE	GLRLM		
Long-run low grey-level emphasis	GLRLM_LRLGE	GLRLM		
Long-run high grey-level emphasis	GLRLM_LRHGE	GLRLM		
Grey-level non-uniformity for run	GLRLM_GLNU	GLRLM		
Run length non-uniformity	GLRLM_RLNU	GLRLM		
Run percentage	GLRLM_RP	GLRLM		
Coarseness	NGLDM_Coarseness	The neighbourhood grey-level different matrix (NGLDM)		
Contrast	NGLDM_Contrast	NGLDM		
Busyness	NGLDM_Busyness	NGLDM		
Short-zone emphasis	GLZLM_SZE	The grey-level zone length matrix (GLZLM)		
Long-zone emphasis	GLZLM_LZE	GLZLM		
Low grey-level zone emphasis	GLZLM_LGZE	GLZLM		
High grey-level zone emphasis	GLZLM_HGZE	GLZLM		
Short-zone low grey-level emphasis	GLZLM_SZLGE	GLZLM		
Short-zone high grey-level emphasis	GLZLM_SZHGE	GLZLM		
Long-zone low grey-level emphasis	GLZLM_LZLGE	GLZLM		
Long-zone high grey-level emphasis	GLZLM_LZHGE	GLZLM		
Grey-level non-uniformity for zone	GLZLM_GLNU	GLZLM		
Zone length non-uniformity	GLZLM_ZLNU	GLZLM		
Zone percentage	GLZLM_ZP	GLZLM		



Figure 3. Show a box plot of metabolic parameters in Siemens vs. LIFEx software. A) Metabolic tumour volume (MTV) in both software. B) A SUV_{max} and SUV_{max} in each software

in this study can be found at: https://lifexsoft.org/index. php/resources/19-texture/radiomicfeatures?filter_tag [0]=.

Statistical analysis

A paired *t*-test was used to obtain the differences between the metabolic and radiomics features in 3D and 2D mode, and then the Spearman correlation coefficient was calculated to study the relationship between metabolic and radiomics features and the tumour staging, diameter, and metabolic volume. All statistical tests were calculated using Origin lab software version 6 and IBM-SPSS version 19.

Results

SUV values (SUV_{max}, SUV_{mean}, and MTV) were compared between the LIFEx package and an approved software: Siemens Syngo trueD. An independent *t*-test for the values in both software calculated to measure the differences between the values. SUV_{mean} was the most stable feature between the two software packages, with a significance level (ρ) = 0.91, where MTV and SUV_{max} gave (ρ) = 0.87 and 0.61, respectively. There was no significant difference between the two software packages, as shown in Figure 3.

The variations between SUV parameters, except SUV_{min}, and 20 radiomics features were statistically stable in 3D and 2D modes, as shown in Table 2. Most features had ρ -values higher than 0.05; the most stable in the SUV feature was SUV_{mean}, with $\rho = 0.588$, while in radiomics features the most stable were GLCM_Contrast and GLZLM_LGZE, with $\rho = 0.89$ and 0.82, respectively. Around 15 features were significantly different between the 2 modes; the most significant was GLZLM_ZP, with $\rho \leq 0.001$.

Spearman correlation coefficients for both 3D and 2D features with tumour maximum diameter, tumour staging, and tumour metabolic volume are shown in Tables 3 and 4, respectively. Most of 3D mode features showed high correlation with metabolic tumour volume, as shown in Table 3; the strongest correlation of metabolic parameters was found with TLG, with rs = 0.98, and from radiomics features it was GLRLM_RLNU, with rs = 0.97. Considering the 2D mode features, there was no significant correlation between the SUV as well as radiomics features and MTV, AJCC staging, or tumour maximum diameter, where all spearman correlation coefficients were less than 0.3, as shown in Table 4.

To compare HCC tumour heterogeneity through uptake heterogeneity and radiomics features, the relationship between SUV_(std/mean) and GLCM entropy with metabolic tumour volume is shown in Figure 4. The¹⁸F-FDG uptake heterogeneity coefficient SUV_(std/mean) mean value = 0.304 ± 0.14 , and GLCM-entropy radiomics feature mean $= 2.016 \pm 0.523$.

Discussion

Several studies have demonstrated agreement on the usefulness of ¹⁸F[FDG]-PET/CT in defining HCC, staging, and treatment assessment; furthermore, some authors reported a high correlation with histopathology results [22-25]. Our study showed that the addition of radiomics features to PET images can provide more information about cancer structure and intratumour heterogeneity.

Comparing the SUV parameters generated by LIFEx, which is an open-source software, with Siemens Syngovia TrueD (commercial software), there was no significant difference between the two software programs. Arian *et al.* reported differences in SUV parameters through four platforms [26]. On the other hand, Kenny *et al.* compared SUV parameters through 14 software programs using three phantoms calibrated on 3 PET/CT scanners, and agreement found in some software included Siemens TrueD [27].

In the current work we found that SUV_{mean} and $SUV_{(std/mean)}$ were smaller in 3D than in 2D mode, whereas,

 Table 2. The results of paired t-test for metabolic and radiomics features in both 2D and 3D modes; the cells signed with (*) show the significant difference in features between 3D and 2D

Features	t	<i>p</i> -value
SUV _(std/mean)	1.377	0.1782
SUV _{min} (SUV)	-5.557	< 0.0001*
SUV _{mean} (SUV)	-0.546	0.588
SUV _{std} (SUV)	0.767	0.4484
SUV _{max} (SUV)	1.278	0.2104
HISTO_Skewness	0.550	0.5858
HISTO_Kurtosis	0.697	0.4908
HISTO_Entropy_log10	1.491	0.1458
HISTO_Entropy_log2	1.491	0.1458
HISTO_Energy	1.955	0.0594
GLCM_Homogeneity	0.754	0.4562
GLCM_Energy	-1.536	0.1345
GLCM_Contrast	-0.144	0.8861
GLCM_Correlation	3.594	0.0011*
GLCM_Entropy_log10	2.489	0.0182*
GLCM_Entropy_log2	2.489	0.0182*
GLCM_Dissimilarity	-0.277	0.7833
GLRLM_SRE	-1.099	0.2800
GLRLM_LRE	0.475	0.6377
GLRLM_LGRE	-0.742	0.4633
GLRLM_HGRE	-0.28	0.7816
GLRLM_SRLGE	-0.575	0.5691
GLRLM_SRHGE	-0.338	0.7372
GLRLM_LRLGE	-0.952	0.3485
GLRLM_LRHGE	0.586	0.5620
GLRLM_GLNU	5.845	< 0.0001*
GLRLM_RLNU	4.837	< 0.0001*
GLRLM_RP	-0.681	0.5007
NGLDM_Coarseness	-10.763	< 0.001
NGLDM_Contrast	-2.763	0.0094*
NGLDM_Busyness	4.705	< 0.0001*
GLZLM_SZE	-11.597	< 0.0001*
GLZLM_LZE	3.020	0.0049*
GLZLM_LGZE	-0.225	0.8234
GLZLM_HGZE	0.401	0.6908
GLZLM_SZLGE	-1.928	0.0628
GLZLM_SZHGE	-1.526	0.0628
GLZLM_LZLGE	2.243	0.0319*
GLZLM_LZHGE	3.089	0.0041*
GLZLM_GLNU	4.430	0.0001*
GLZLM_ZLNU	2.586	0.0145*
GLZLM_ZP	-12.754	< 0.0001*

 SUV_{max} was little higher in 2D mode than in 3D mode. Kocabaş *et al.* reported that SUV_{max} was variable between 3D and 2D modes and the values were smaller in 3D mode [28]. In the current work we found that SUV_{mean} and $SUV_{(std/mean)}$ were smaller in 3D than in 2D mode, whereas SUV_{max} was a little larger in 2D mode than in 3D mode.

Our study showed a strong correlation of 3D mode features, especially TLG and GLRLM_RLNU with MTV. This strong correlation could be explained by the fact that TLG and GLRLM_RLNU voxel values are not absolute SUV values and depend on the lesion volume. Therefore, it showed a strong correlation with MTV. The lowest correlation of MTV was found with GLRLM_LRLGE. A similar correlation between the same feature and MTV was found by Vicente *et al.* in the case of breast cancer dual time acquisition PET [29]. GLRLM_LRLGE measures the roughness of the images, which increases when the texture is dominated by long runs that have low grey levels; hence, it may not correlate with volume.

In this study, TLG from metabolic parameters and GLRLM_RLNU from radiomics features demonstrated a strong correlation with maximum diameter of the lesion, with rs = 0.75 and 0.71, respectively. Hatt *et al.* reported that MTV has a close correlation with tumour diameter in lung cancer [20]. So, the same correlation can be found in the case of TLG because it depends on MTV, and as we mentioned before: RLNU is correlated to MTV and to the diameter. Regarding AJCC staging, some features showed a medium correlation with metabolic and radiomics features; the strongest was GLZLM_GLNU, with rs = 0.4915. Van Go *et al.* reported a similar correlation between some radiomics features of [¹⁸F] (FDG-PET) images and AJCC staging for non-small cell lung carcinoma (NSCLC) [21].

Considering the 2D mode features, there was no significant correlation between the SUV as well as radiomics features and MTV, AJCC staging, or tumour maximum diameter. This may be because the spatial resolution of PET images is low, which does not give strong texture information in small areas [18].

It has been shown that tumour heterogeneity increases with larger tumour volume, as reported by Hatt *et al.* and Brooks and Grigsby [20,30]. In our cohort we found that some HCC tumours may be more heterogeneous in both uptake and radiomics value without being large in volume, as shown in Figure 5. SUV_{max} is the commonest parameter used for follow-up; however, it suffers from the fact that it is not correlated to tumour volume and tumour heterogeneity. Figure 5 demonstrates a tumour with high SUV_{max} , but its textural analysis is less heterogeneous than another tumour with lower SUV_{max} value. Hatt *et al.* suggested that GLCM entropy with MTV is lower in the volume range less than 50 cm³ [31]; this finding is in agreement with our study.

Limitations of our study include the relatively small sample size, restricted number of radiomics features, and

 Table 3. Spearman correlation coefficient rs and ρ -values for metabolic and radiomics features in 3D mode with tumour metabolic volume, tumour staging, and maximum diameter; cells signed with (*) are medium correlation where cells signed with (**) are high correlation

3D features	Diameter (rs)	Diameter (p)	AJCC staging	AJCC staging	MTV (rs)	MTV (ρ)
			(rs)	(ρ)		
SUV _{mean/std}	0.5019	0.0029**	0.3242	0.0657*	0.6090	0.0002**
SUV _{min} (SUV)	-0.5439	0.0011**	-0.2844	0.1087	-0.5505	0.0009**
SUV _{mean} (SUV)	0.3246	0.0654*	0.4177	0.0156*	0.5114	0.0024**
_SUV _{std} (SUV)	0.4400	0.0104*	0.3509	0.0453*	0.6123	0.0002**
SUV _{max} (SUV)	0.4882	0.0040*	0.4108	0.0176*	0.6928	< 0.0001**
SUV _{peak} 1 ml	0.4903	0.0038	0.3799	0.0292*	0.6801	< 0.0001**
TLG (ml)	0.7461	< 0.0001**	0.4556	0.0077*	0.9776	< 0.0001**
HISTO_Skewness	0.3281	0.0623*	0.1334	0.4592	0.4679	0.006*
HISTO_Kurtosis	0.2966	0.0937	-0.0407	0.8222	0.3382	0.0542*
HISTO_Entropy_log10	0.4500	0.0086*	0.3554	0.0424*	0.6230	0.0001**
HISTO_Energy	-0.4323	0.0120*	-0.3452	0.0491*	-0.5946	0.0003**
Sphericity (only for 3D ROI)	-0.2573	0.1483	-0.4117	0.0173*	-0.5003	0.0030**
SHAPE_Compacity ROI (nZ > 1)	0.7363	< 0.0001**	0.3128	0.0764*	0.9542	< 0.0001**
GLCM_Homogeneity	-0.2991	0.0908	-0.3118	0.0773*	-0.4602	0.007*
GLCM_Energy	-0.4090	0.0181*	-0.3576	0.041*	-0.5872	0.0003**
GLCM_Contrast	0.3269	0.0633*	0.3358	0.0561*	0.4773	0.0050*
GLCM_Correlation	0.6277	< 0.0001**	0.2483	0.1635	0.7614	< 0.0001**
GLCM_Entropy_log10	0.4323	0.0120*	0.3805	0.0289*	0.6096	0.0002**
GLCM_Dissimilarity	0.3145	0.0746*	0.3340	0.0575*	0.4766	0.0050*
GLRLM_SRE	0.1169	0.5190	0.2701	0.1285	0.2012	0.2615
GLRLM_LRE	-0.0875	0.6283	-0.2556	0.1511	-0.1310	0.4674
GLRLM_LGRE	-0.1273	0.4802	-0.2668	0.1333	-0.2707	0.1276
GLRLM_HGRE	0.3460	0.0486*	0.4115	0.0174*	0.5394	0.0012**
GLRLM_SRLGE	-0.1521	0.3982	-0.324	0.0658*	-0.3185	0.0708*
GLRLM_SRHGE	0.3314	0.0596*	0.4218	0.0145*	0.5124	0.0023**
GLRLM_LRLGE	-0.0087	0.9617	-0.1133	0.5303	-0.0745	0.6802
GLRLM_LRHGE	0.3883	0.0256*	0.4538	0.0080*	0.6380	< 0.0001**
GLRLM_GLNU	0.6943	< 0.0001**	0.2672	0.1328	0.8930	< 0.0001**
GLRLM_RLNU	0.7143	< 0.0001**	0.4324	0.0120*	0.9733	< 0.0001**
GLRLM_RP	0.1074	0.5519	0.2334	0.1911	0.1852	0.3023
NGLDM_Coarseness	-0.711	< 0.0001**	-0.3993	0.0213*	-0.9652	< 0.0001**
NGLDM_Contrast	-0.0054	0.9764	0.181	0.3135	0.0896	0.6201
NGLDM_Busyness	0.3197	0.0697*	0.0937	0.6041	0.4676	0.0061*
GLZLM_SZE	0.3018	0.0878*	0.46	0.0071*	0.3061	0.0831*
GLZLM_LZE	0.1057	0.5581	-0.1296	0.4722	0.1407	0.4348
GLZLM_LGZE	-0.311	0.0781*	-0.4422	0.0100*	-0.5043	0.0028**
GLZLM_HGZE	0.4122	0.0171*	0.4149	0.0163*	0.6243	0.0001**
GLZLM_SZLGE	-0.3756	0.0312*	-0.3683	0.0350*	-0.6233	0.0001**
GLZLM_SZHGE	0.4042	0.0197*	0.4110	0.0175*	0.5929	0.0003**
GLZLM_LZLGE	0.1910	0.2869	-0.0546	0.7627	0.2176	0.2239
GLZLM_LZHGE	0.1793	0.3180	-0.1036	0.5660	0.2654	0.1355
GLZLM_GLNU	0.6590	< 0.0001**	0.4915	0.0037*	0.9181	< 0.0001**
GLZLM_ZLNU	0.6412	< 0.0001**	0.4607	0.0070*	0.8590	< 0.0001**
GLZLM_ZP	0.1273	0.4802	0.2988	0.0912	0.1888	0.2926

Table 4. Spearman correlation coefficient (rs) and *p*-values for metabolic and radiomics features in 2D mode with tumour metabolic volume, tumour staging, and maximum diameter

2D features	Diameter (rs)	Diameter	AJCC staging (rs)	AJCC satging	MTV (rs)	MTV
SUV	-0.0368	0.8389	0.0310	0.8638	-0.0842	0 6412
SUV (SUV)	0.1086	0.5475	-0.0033	0.9856	0.1889	0.2925
SUV (SUV)	0.0746	0.6798	0.0969	0.5915	0.1300	0.4708
SUV (SUV)	-0.0666	0.7127	0.0209	0.9082	-0.0154	0.9323
SUV (SUV)	0.0698	0.6996	0.0830	0.6400	0.1183	0.5119
HISTO Skewness	0.0740	0.6825	0.0924	0.6090	0.0568	0.7535
HISTO Kurtosis	0.1302	0.4703	-0.1278	0.4785	0.0739	0.6829
HISTO Entropy log10	-0.0746	0.6798	0.0162	0.9289	-0.0294	0.8709
HISTO_Energy	0.0289	0.8730	-0.0172	0.9241	0.0137	0.9397
GLCM_Homogeneity	0.0612	0.7350	-0.0419	0.8168	0.0160	0.9294
GLCM_Energy	0.0256	0.8876	-0.0064	0.9720	0.0160	0.9294
GLCM_Contrast	-0.1024	0.5707	0.0592	0.7436	-0.0475	0.7931
GLCM_Correlation	0.0492	0.7857	-0.0007	0.9968	0.0150	0.9338
GLCM_Entropy_log10	-0.0385	0.8316	-0.0167	0.9265	-0.0053	0.9764
GLCM_Dissimilarity	-0.0920	0.6105	0.0494	0.7849	-0.0331	0.8549
GLRLM_SRE	-0.0669	0.7114	-0.0719	0.6910	-0.0104	0.9544
GLRLM_LRE	0.1066	0.5550	-0.0719	0.6910	0.0468	0.7959
GLRLM_LGRE	-0.1384	0.4425	-0.077	0.6703	-0.1842	0.3049
GLRLM_HGRE	0.0815	0.6522	0.0782	0.6650	0.1257	0.4859
GLRLM_SRLGE	-0.1663	0.3550	-0.0824	0.6484	-0.2276	0.2027
GLRLM_SRHGE	0.0882	0.6256	0.0868	0.6311	0.1270	0.4812
GLRLM_LRLGE	-0.0728	0.6873	-0.0866	0.6320	-0.1217	0.5000
GLRLM_LRHGE	0.1755	0.3286	0.0902	0.6180	0.2704	0.1280
GLRLM_GLNU	0.1494	0.4066	-0.2200	0.2180	0.0956	0.5967
GLRLM_RLNU	0.1389	0.4409	-0.0381	0.8330	0.0929	0.6070
GLRLM_RP	-0.0793	0.6609	0.0713	0.6932	-0.0237	0.8957
NGLDM_Coarseness	-0.2543	0.1532	-0.0378	0.8347	-0.2129	0.2342
NGLDM_Contrast	-0.1594	0.3754	0.0084	0.9632	-0.1080	0.5498
NGLDM_Busyness	0.1300	0.4709	0.0336	0.8528	0.1003	0.5787
GLZLM_SZE	-0.0612	0.7350	0.0080	0.9640	-0.0642	0.7227
GLZLM_LZE	0.0766	0.6717	-0.0944	0.6013	0.0254	0.8884
GLZLM_LGZE	-0.1466	0.4157	-0.0920	0.6105	-0.1999	0.2647
GLZLM_HGZE	0.0863	0.6329	0.1106	0.5402	0.1337	0.4582
GLZLM_SZLGE	-0.1464	0.4163	-0.0871	0.6290	-0.2086	0.2441
GLZLM_SZHGE	0.0447	0.8050	0.0986	0.5852	0.0889	0.6230
GLZLM_LZLGE	0	1	-0.0958	0.5957	-0.0428	0.8131
GLZLM_LZHGE	0.2553	0.1516	0.0425	0.8144	0.2707	0.1275
GLZLM_GLNU	0.1516	0.3525	-0.1690	0.3471	0.0789	0.6626
GLZLM_ZLNU	0.0617	0.7329	-0.0134	0.9409	0.0328	0.8564
GLZLM_ZP	-0.0795	0.6602	0.0801	0.6579	-0.0428	0.8131

lack of comparison of the findings with other clinical information such histopathology results. The clinical course of the disease and liver functions have not been compared with radiomics. However, the main focus of this investigation was to improve the performance of FDG-PET/CT in the diagnosis and characterisation of HCC, which will be extended in our future works to incorporate radiomics in clinical practice. Furthermore, there was medical value to our finding: we discovered the best mode for HCC radiomics for use in our future studies.

Conclusions

The metabolic parameters and radiomics features are variable between 3D and 2D modes. Some SUV parameters and radiomics features are statically stable through 3D and 2D modes. Image analysis in 3D radiomics features is significantly correlated with tumour volume, maximum diameter, and staging, whereas all features in 2D exhibit no correlation. Therefore, in comprehensive studies of intra-tumoral structure, 3D mode features can accurately evaluate tumour heterogeneity.



Figure 4. The correlation of $SUV_{std/mean}$ and GLCM entropy with metabolic tumour volume (MTV)

Conflict of interest

The authors report no conflict of interest.



Figure 5. Comparison between two hepatocellular carcinoma (HCC) tumour parameters. (A) and (B) compare uptake heterogeneity coefficient and GLCMentropy of two HCC tumours. Although (B) have a higher metabolic tumour volume, it is more homogenous than tumour (A). (C) and (D) compare the parameters for the same patient in 2D and 3D, respectively

References

- Balogh J, Iii Dv, Asham Eh, et al. Hepatocellular carcinoma : a review. J Hepatocell Carcinoma 2016; 3: 41-53.
- 2. Hammoud GM, Ibdah JA. Are we getting closer to understanding intratumor heterogeneity in hepatocellular carcinoma? Hepatobiliary Surg Nutr 2016; 5: 188-190.
- Davnall F, Yip CSP, Ljungqvist G, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 2012; 3: 573-589.
- 4. Lambin P, Rios-velazquez E, Leijenaar R. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48: 441-446.
- Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014; 5: 4006.
- Coroller TP, Sc M, Grossmann P, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 2016; 114: 345-350.
- 7. Mackin D, Fave X, Zhang L, et al. Measuring CT scanner variability of radiomics features. Invest Radiol 2015; 50: 757-765.
- 8. Parmar C, Leijenaar RTH, Grossmann P, et al. Radiomic feature clusters and prognostic signatures specific for lung and head and neck cancer. Sci Rep 2015; 5: 11044.
- Altazi BA, Zhang GG, Fernandez DC, et al. Reproducibility of F18-FDG PET radiomic features for different cervical tumor segmentation methods, gray-level discretization, and reconstruction algorithms. J Appl Clin Med Phys 2017; 18: 32-48.
- Depeursinge A, Foncubierta-Rodriguez A, Van De Ville D, Müller H. Three-dimensional solid texture analysis in biomedical imaging: review and opportunities. Medical Image Analysis 2014; 18: 176-196.
- Mahmoud-Ghoneim D, Toussaint G, Constans JM, De Certaines JD. Three dimensional texture analysis in MRI: A preliminary evaluation in gliomas. Magn Reson Imaging 2003; 21: 983-987.
- Lubner MG, Stabo N, Lubner SJ, et al. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging 2015; 40: 2331-2337.
- Ortiz-Ramon R, Larroza A, Arana E, Moratal D. A radiomics evaluation of 2D and 3D MRI texture features to classify brain metastases from lung cancer and melanoma. Proc Annu Int Conf IEEE Eng Med Biol Soc 2017; 2017: 493-496.
- Amin M, Edge S, Greene F, et al. (eds.). AJCC Cancer Staging Manual. Springer International Publishing 2017; 287-293.
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-1314.
- Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-337.
- Nioche C, Orlhac F, Boughdad S, et al. Lifex: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 2018; 78: 4786-4789.

- Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
- Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999; 2: 159-171.
- Hatt M, Cheze-le Rest C, van Baardwijk A, et al. Impact of tumor size and tracer uptake heterogeneity in 18F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med 2011; 52: 1690-1697.
- 21. Van Gómez López O, García Vicente AM, Honguero Martínez AF, et al. Heterogeneity in [18 F]fluorodeoxyglucose positron emission tomography/computed tomography of non small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging. Mol Imaging 2014; 13; doi: 10.2310/7290.2014.00032.
- Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817.
- 23. Wolfort RM, Papillion PW, Turnage RH, et al. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg 2010; 95: 67-75.
- 24. Kitamura K, Hatano E, Higashi T, et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 156-162.
- Dong A, Yu H, Wang Y, et al. FDG PET/CT and enhanced CT imaging of tumor heterogeneity in hepatocellular carcinoma: imaging-pathologic correlation. Clin Nucl Med 2014; 39: 808-810.
- Arain Z, Lodge M, Wahl R. A comparison of SUV parameters across four commercial software platforms. J Nucl Med 2015; 56 (Suppl 3): 580.
- 27. Kenny B. SUV reproducibility on different reporting platforms What is SUV? BNMS spring meeting, Birmingham 2016.
- Kocabas B, Yapar AF, Reyhan M, et al. Comparison of standardized uptake values obtained from 18F fluorodeoxyglucose positron emission tomography/computed tomography imaging performed with 2d and 3D modes in oncological cases. Diagnostic Interv Radiol 2012; 126-129.
- Garcia-Vicente AM, Molina D, Pérez-Beteta J, et al. Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer. Ann Nucl Med 2017; 31: 726-735.
- Brooks FJ, Grigsby PW. The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med 2013; 55: 37-42.
- 31. Hatt M, Majdoub M, Vallières M, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 2015; 56: 38-44.